



CPA-100US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jialum Chen, et al. : Art Unit: 1642  
Serial No.: 09/554,945 : Examiner: M. Davis  
Filed: May 22, 2000 :  
For: A HUMAN Hsg III GENE :

RECEIVED

AUG 22 2001

TECH CENTER 1600/2900

DECLARATION OF  
SEQUENCE LISTING UNDER 37 C.F.R. § 1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231

SIR:

In response to the Restriction Requirement of July 17, 2001, with Notice To Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures attached, please amend the sequence listing as follows and consider the following remarks:

AMENDMENT TO THE SEQUENCE LISTING

Please delete the sequence listing and insert, therefor, the attached sequence listing.

REMARKS

Responsive to the Notice To Comply of July 17, 2001, Applicants request replacement of the sequence listing.

Submitted herewith is an amended sequence listing in computer readable form and in paper copy form. The sequence listing has been amended to correct errors. The amendment to the sequence listing is supported by the originally filed sequence listing. No new matter has been added.

Applicants make the statement that the information recorded in computer readable form is identical to the written sequence listing. This submission complies with the sequence requirements of 37 C.F.R. § 1.821 through § 1.825.

Respectfully submitted,

RATNER & PRESTIA



Robert L. Andersen, Reg. No. 25,771

Attorney for Applicants

Camille Jolly-Tornetta, Reg. No. P-48,592

/fp

Date: August 17, 2001

Suite 301

One Westlakes (Berwyn)

P. O. Box 980

Valley Forge, PA 19482-0980

(610) 407-0700 Phone

(610) 407-0701 Fax

The Assistant Commissioner for Patents is hereby authorized to charge payment to Deposit Account No. **18-0350** of any fees associated with this communication.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on:

August 17, 2001



**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7.

Other: \_\_\_\_\_

**RECEIVED**

AUG 22 2001

TECH CENTER 1600/2900

**Applicant must provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

**Please return a copy of this notice with your response.**